HRV Pharma acquires German Phatebo to enter European finished-dose pharmaceuticals market
India's HRV Pharma has acquired Germany-based Phatebo GmbH, establishing a European platform for finished-dose pharmaceuticals and clinical-trial supply services beyond its existing active pharmaceutical ingredients business.
The completed acquisition announced on 3 November 2026 gives HRV Pharma full ownership of Phatebo, a licensed pharmaceutical wholesaler and clinical supply specialist acquired from ZeroStack Corp, while retaining the German company's existing name, management and workforce.
Financial consideration was not disclosed, and Phatebo's reported approximately ₹350 crore in 2025 revenue should be understood as a business performance figure rather than the transaction price.
Field | Content |
Article Type | Deals |
Acquirer | HRV Pharma |
Acquired Company | Phatebo GmbH |
Seller | ZeroStack Corp |
Deal Type | Completed cross-border pharmaceutical acquisition |
Announcement Date | 3 November 2026 |
Transaction Status | Completed |
Equity Stake Acquired | 100% |
Acquired Company Location | Germany |
Acquirer Country | India |
Geographic Expansion | European pharmaceutical market |
Acquired Business Type | Licensed pharmaceutical wholesaler and clinical-trial supply specialist |
Existing Acquirer Focus | Active pharmaceutical ingredients |
New Business Focus | Finished-dose pharmaceutical formulations and clinical supply |
Acquired Company Operating Name | Phatebo GmbH retained |
Management Continuity | Existing management retained |
Workforce Continuity | Existing team retained |
Subsidiary Status | Wholly owned subsidiary of HRV Pharma |
Reported Acquired Company Revenue | Approximately ₹350 crore in 2025 |
Transaction Consideration | Not disclosed |
Financial Clarification | Reported 2025 revenue is not the acquisition purchase price |
Therapeutic Areas | Not specified in supplied summary |
What Happened | HRV Pharma acquired 100% of Phatebo GmbH from ZeroStack Corp to expand into European finished formulations and clinical supply operations. |
Why It Matters | The acquisition provides HRV with an established German pharmaceutical business and a platform for moving beyond API supply into finished-dose products and clinical services. |
Strategic Rationale | Diversify pharmaceutical operations and establish a stronger commercial and supply-chain presence in Europe. |
Operational Integration | Phatebo will continue under its existing name, management and team as an HRV subsidiary. |
Key Takeaway | HRV Pharma has completed a European acquisition that broadens its business beyond APIs, with financial terms undisclosed. |
What to Watch | European market expansion, finished-formulation portfolio development, clinical supply partnerships and post-acquisition integration. |
Primary Source | Business Standard reporting |
Primary Source URL | https://www.business-standard.com/companies/news/hrv-pharma-acquires-german-firm-phatebo-enters-finished-formulations-biz-126110301623_1.html |
Relevant Date | 3 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare